Clene’s (CLNN) “Buy” Rating Reaffirmed at HC Wainwright

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Monday, Benzinga reports.

Separately, Weiss Ratings upgraded shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Clene Price Performance

Shares of CLNN traded up $0.21 on Monday, hitting $3.31. The company’s stock had a trading volume of 53,666 shares, compared to its average volume of 220,685. The company has a market capitalization of $43.04 million, a PE ratio of -0.94 and a beta of 0.91. Clene has a fifty-two week low of $3.02 and a fifty-two week high of $13.50. The company has a 50 day moving average price of $4.04 and a 200 day moving average price of $5.33.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Friday, August 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, equities analysts forecast that Clene will post -1.70 EPS for the current year.

About Clene

Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.

Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.